Jazz Pharmaceuticals plc (JAZZ)
Company Info
Highlights
$6.72B
$7.56
14.42
3.89
$4.06B
$3.45B
$1.28B
$95.49 - $148.06
$184.00
10.00%
4.12
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Jazz Pharmaceuticals plc (JAZZ) returned -11.51% year-to-date (YTD) and -0.01% over the past 12 months. Over the past 10 years, JAZZ returned -4.95% annually, underperforming the S&P 500 benchmark at 10.89%.
JAZZ
-11.51%
6.03%
-10.42%
-0.01%
-1.20%
-4.95%
^GSPC (Benchmark)
1.30%
12.79%
1.49%
12.35%
15.12%
10.89%
Monthly Returns
The table below presents the monthly returns of JAZZ, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 0.99% | 15.41% | -13.50% | -5.79% | -6.82% | -11.51% | |||||||
| 2024 | -0.23% | -3.11% | 1.28% | -8.03% | -4.97% | 1.41% | 3.30% | 5.20% | -3.94% | -1.24% | 10.51% | 1.28% | 0.12% |
| 2023 | -1.66% | -10.38% | 4.22% | -4.00% | -8.76% | -3.27% | 5.20% | 9.92% | -9.71% | -1.87% | -6.92% | 4.03% | -22.79% |
| 2022 | 9.03% | -1.07% | 13.28% | 2.92% | -6.58% | 4.23% | 0.03% | -0.54% | -14.13% | 7.88% | 9.12% | 1.53% | 25.05% |
| 2021 | -5.79% | 8.06% | -2.18% | 0.02% | 8.35% | -0.28% | -4.57% | -22.30% | -1.14% | 2.17% | -9.90% | 6.28% | -22.81% |
| 2020 | -3.97% | -20.07% | -12.95% | 10.54% | 8.23% | -7.53% | -1.89% | 24.15% | 6.10% | 1.06% | -2.35% | 17.30% | 10.56% |
| 2019 | 1.56% | 11.23% | 2.09% | -9.22% | -3.25% | 13.55% | -2.23% | -8.06% | -0.01% | -1.96% | 20.29% | -1.22% | 20.43% |
| 2018 | 8.24% | -0.64% | 4.27% | 0.70% | 11.15% | 1.95% | 0.45% | -1.25% | -1.63% | -5.54% | -4.80% | -18.02% | -7.94% |
| 2017 | 11.82% | 8.78% | 9.43% | 9.75% | -8.61% | 6.83% | -1.22% | -2.77% | -2.08% | -3.23% | -1.26% | -3.64% | 23.50% |
| 2016 | -8.41% | -5.56% | 7.38% | 15.43% | 0.57% | -6.76% | 6.84% | -17.98% | -1.90% | -9.89% | -5.33% | 5.21% | -22.43% |
| 2015 | 3.43% | 0.44% | 1.59% | 3.42% | 0.36% | -1.83% | 9.18% | -12.18% | -21.33% | 3.37% | 6.78% | -4.11% | -14.15% |
| 2014 | 19.83% | 0.19% | -8.73% | -2.73% | 5.16% | 3.63% | -4.95% | 16.60% | -1.45% | 5.16% | 4.89% | -7.54% | 29.37% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of JAZZ is 44, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Jazz Pharmaceuticals plc (JAZZ) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Jazz Pharmaceuticals plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Jazz Pharmaceuticals plc was 96.90%, occurring on Apr 23, 2009. Recovery took 407 trading sessions.
The current Jazz Pharmaceuticals plc drawdown is 43.54%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -96.9% | Jun 4, 2007 | 477 | Apr 23, 2009 | 407 | Dec 3, 2010 | 884 |
| -54.54% | Jul 29, 2015 | 1171 | Mar 23, 2020 | — | — | — |
| -28.77% | Feb 26, 2014 | 29 | Apr 7, 2014 | 163 | Nov 26, 2014 | 192 |
| -25.64% | Sep 21, 2011 | 36 | Nov 9, 2011 | 40 | Jan 9, 2012 | 76 |
| -23.17% | Apr 18, 2011 | 26 | May 24, 2011 | 27 | Jul 1, 2011 | 53 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Jazz Pharmaceuticals plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Jazz Pharmaceuticals plc, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -63.9%.
Valuation
The Valuation section provides an overview of how Jazz Pharmaceuticals plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for JAZZ, comparing it with other companies in the Biotechnology industry. Currently, JAZZ has a P/E ratio of 14.4. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for JAZZ compared to other companies in the Biotechnology industry. JAZZ currently has a PEG ratio of 3.9. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for JAZZ relative to other companies in the Biotechnology industry. Currently, JAZZ has a P/S ratio of 1.7. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for JAZZ in comparison with other companies in the Biotechnology industry. Currently, JAZZ has a P/B value of 1.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |